Q4 FY2024 · ended Dec 31, 2024 · Revenue $213,000 · Filed Apr 15, 2025
Vaccinex, Inc. (VCNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2024, the quarter ended Dec 31, 2024, it reported revenue of $213,000 and a net loss of $3.4 million. Free cash flow was -$3.9 million. As of Dec 31, 2024 it held $1.1 million in cash and investments and $25,000 in total debt.
Revenue
$213,000
Net income
$-3.37M
-1.7% vs year-ago quarter
Operating cash flow
$-3.93M
+49.2% vs year-ago quarter
Free cash flow
$-3.93M
+49.2% vs year-ago quarter
EPS
$-1.05
+68.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.68M
+117.3% vs year-ago quarter
Net cash
$1.08M
Q4 FY2024
Operating margin
-1590.1%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VCNX (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rochester, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1205922
- Former names
- VACCINEX INC (until May 9, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
Q2 FY2024 Jun 30, 2024 |
Q1 FY2024 Mar 31, 2024 |
Q4 FY2023 Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue | $213,000 | $52,000 | $232,000 | $104,000 | $0 |
| Operating income | -$3.4M | -$4.6M | -$5.7M | -$5.1M | -$5.0M |
| Net income | -$3.4M | -$5.7M | -$5.6M | -$3.9M | -$3.3M |
| Diluted EPS | -$1.05 | -$2.83 | -$3.10 | -$2.94 | -$3.32 |
| Operating cash flow | -$3.9M | -$3.2M | -$4.4M | -$4.6M | -$7.7M |
| Free cash flow | -$3.9M | -$3.2M | -$4.4M | -$4.6M | -$7.7M |
| Total assets | $2.6M | $4.9M | $2.4M | $7.4M | $3.6M |
| Total liabilities | $5.1M | $6.2M | $5.2M | $4.7M | $5.9M |
| Stockholders' equity | -$2.5M | -$1.3M | -$2.9M | $2.7M | -$2.3M |
| Cash and investments | $1.1M | $2.9M | $233,000 | $3.0M | $1.5M |
| Total debt | $25,000 | $58,961 | $122,325 | $184,922 | $246,764 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 19, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Mar 7, 2025 | Mar 7, 2025 |
| 8-K |
Current report
Listing notice, Other events
|
Dec 17, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 14, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
All 475 Vaccinex, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.